Postoperative chemotherapy use and survival in non-high-risk young and high-risk old-aged patients with stage II colon cancer

Author:

Jin Tian,Zhu Yingshuang,Lu Wei,Le Chenqin,Wang Lijuan,Xiao Qian,Ding Kefeng

Abstract

Abstract Purpose Intensive postoperative chemotherapy treatment use in early-onset colon cancer and late-onset colon cancer remains to be defined and their effects on prognosis were unclear. This study aims to investigate whether intensive adjuvant chemotherapy for stage II colon cancer would result in matched survival improvement in young patients (< 50 years) without risk factors and old-aged (70–85 years) patients with risk factors defined by guidelines. Methods We extracted eligible patients with pathologically confirmed TNM stage II colon cancer from the Surveillance, Epidemiology, and End Results database between 2004 and 2015. Patients aged < 50 years old without risk factors were defined as non-high-risk early-onset colon cancer (non-HREOCC), and those aged 70 to 85 years with risk factors were defined as high-risk late-onset colon cancer (HRLOCC). Kaplan–Meier (KM) method with log-rank test was performed to calculate the overall survival (OS) and cancer-specific survival (CSS). Multivariate Cox model was used to estimate the association of adjuvant chemotherapy with CSS by adjusting potential confounding factors. Results Of 55,366 eligible stage II colon cancer patients, 3341 non-HREOCC patients and 11,722 HRLOCC patients were included. 37.68% and 16.8% of patients received adjuvant chemotherapy among non-HREOCC and HRLOCC patients, respectively. For non-HREOCC patients, there was no significant association between adjuvant chemotherapy and CSS (HR = 1.09, 95%CI0.83–1.44). For HRLOCC patients, adjuvant chemotherapy was associated with a better CSS (HR = 0.88, 95%CI0.79–0.99). Conclusion Our findings suggested that potential overuse of adjuvant chemotherapy among non-high-risk young patients with stage II colon cancer did not lead to survival improvement, and caution should be called when using chemotherapy in these patients. However, chemotherapy can be used appropriately for high-risk stage II colon cancer patients aged 70 to 85 years.

Funder

Fundamental Research Funds for the Central Universities

Publisher

Springer Science and Business Media LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3